Chest
Clinical InvestigationsFive-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization
Section snippets
Materials and Methods
This randomized, double-blind, parallel-group study took place at 105 centers in 14 countries. The study was performed in accordance with Good Clinical Practice guidelines and was approved by the independent ethics committee of each center. All patients provided written informed consent prior to enrollment.
Results
A total of 650 patients from 14 countries were enrolled into the study between March 14, 2001, and January 11, 2002 (Argentina, n = 28; Australia/New Zealand, n = 44; Belgium, n = 24; Brazil, n = 5; Canada, n = 54; Chile, n = 21; Germany, n = 82; Italy, n = 16; Mexico, n = 18; South Africa, n = 72; Spain, n = 4; Turkey, n = 18; United States, n = 264). Of these, 554 patients were randomized to receive treatment with either telithromycin, 800 mg qd for 5 days (n = 272), or clarithromycin, 500 mg
Discussion
In this study, a 5-day treatment course of telithromycin, 800 mg qd, was as effective and as well tolerated as a 10-day course of clarithromycin, 500 mg bid, for the treatment of AECB in adult patients. Furthermore, in a prospective, blinded evaluation of health-care resource utilization, telithromycin treatment was associated with significantly fewer RTI-related hospitalizations (defined as “AECB-related” plus “other respiratory-related” hospitalizations), significantly fewer AECB-related ED
References (34)
- et al.
Acute exacerbations of chronic bronchitis: an international comparison
Chest
(1998) - et al.
Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study
Pulm Pharmacol Ther
(2001) - et al.
Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD)
Respir Med
(2001) - et al.
Treatment cost of acute exacerbations of chronic bronchitis
Clin Ther
(1999) - et al.
The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales
Value Health
(2001) - et al.
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD
Chest
(2002) - et al.
Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis
Clin Ther
(1998) - et al.
Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis
Respir Med
(2002) Multicenter comparison of azithromycin and amoxicillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease
Curr Ther Res
(1995)- et al.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
Ann Intern Med
(1987)
Acute exacerbations of chronic bronchitis: the clinical problem, patient profiles and recommendations (guidelines) for therapy
J Infect Dis Antimicrob Agents
Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis
JAMA
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease
N Engl J Med
Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection
Am J Respir Crit Care Med
The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
J Antimicrob Chemother
Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin
J Infect
Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America
J Chemother
Cited by (21)
Carbohydrate-based drugs launched during 2000−2021
2022, Acta Pharmaceutica Sinica BCitation Excerpt :Annually, approximately 600,000 patients are hospitalized for CAP in the United States, resulting in $10.6 billion in health care expenditures144. The pooled analysis of several III/IV phase studies indicated that the clinical cure rate and bacteriologic eradication rate of oral telithromycin (12) treatment (800 mg/day) for 5 or 7–10 days reached 88.1% and 89.0%, respectively140,145. Thus, CAP became the first approved indication for telithromycin (12) in 2001146.
Short- vs Long-Course Antibiotics for Acute Exacerbations of Chronic Bronchitis
2012, Journal for Nurse PractitionersCitation Excerpt :The secondary outcomes were late clinical cure and bacteriological cure rates. The moderately strong and consistent results of Fogarty et al's5 study demonstrated that clinical cure rates in the PP population at the posttherapy/test-of-cure (TOC) visit were comparable between the treatment groups (5-day telithromycin = 85.8%, 10-day clarithromycin = 89.2%; difference = −3.4; 95% CI, −9.9, 3.1). The clinical cure rates in the modified ITT group at the posttherapy/TOC visits were also equivalent between groups (telithromycin = 83%, clarithromycin = 83.7%; difference = −0.7; 95% CI, −7.3, 5.9).
Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline)
2011, Medical Clinics of North AmericaMacrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline
2009, Infectious Disease Clinics of North AmericaAcute exacerbation of chronic obstructif pulmonary disease and antibiotics: analysis of comparative trials
2006, Medecine et Maladies Infectieuses
This study was sponsored by sanofi-aventis, USA.
Dr. Mandell has received funding from Aventis, Bayer, Ortho- McNeil, Pfizer, and Wyeth. Dr. Nusrat is employed by sanofiaventis, and Dr. Chang and Dr. Rangaraju are former employees of sanofi-aventis. Dr. Fogarty has received funding from Astra- Zeneca, Aventis, Bayer, Boehringer, GlaxoSmithKline, Lilly, Ortho-McNeil, Organon, Pfizer, and Sepracor.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).